^
    2d
    FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Completed, Fate Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT576
    3d
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    TQB2934
    4d
    Plan Development for Giving Teclistamab in the Outpatient Setting (clinicaltrials.gov)
    P4, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Apr 2025 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • Tecvayli (teclistamab-cqyv)
    9d
    EMN39: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=1000, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Lynozyfic (linvoseltamab-gcpt)
    9d
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=157, Not yet recruiting, Janssen Research & Development, LLC
    New P2 trial
    |
    JNJ-5322
    9d
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    podentamig (MK-4002)
    9d
    Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P1/2 trial
    |
    TQB2934
    11d
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    12d
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    JNJ-5322 • Tecvayli (teclistamab-cqyv)
    19d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    19d
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Tecvayli (teclistamab-cqyv)
    25d
    Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Candid Therapeutics
    New P1 trial